1-4 of 4
Daniel Kientz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4820.
https://doi.org/10.1182/blood.V122.21.4820.4820
Published: 2013
Journal Articles

Retention of Thrombin Generation Capacity of Therapeutic Apheresis Plasma Prepared with Amotosalen and UVA Light (INTERCEPT) Pathogen Inactivation.

Jean-Pierre Cazenave, MD, PhD, Pierre Netzer, Simone Schuhler, Catherine Ravanat, PhD, Hervé Isola, Daniel Kientz, MD, Christian Gachet, MD, PhD, Marie-Louise Wiesel, MD
Journal: Blood
Blood (2007) 110 (11): 4027.
https://doi.org/10.1182/blood.V110.11.4027.4027
Published: 2007
Journal Articles

Coagulation Factor Activity in Therapeutic Plasma Prepared from Whole Blood with Pathogen Inactivation (INTERCEPT ™ ) Treatment.

Jean-Pierre Cazenave, Hervé Isola, Marie-Louise Wiesel, Daniel Kientz, Michel Laforêt, Linda Pinkoski, Yasmin Singh, Laurence Corash
Journal: Blood
Blood (2006) 108 (11): 4149.
https://doi.org/10.1182/blood.V108.11.4149.4149
Published: 2006
Journal Articles

Coagulation Factors in Therapeutic Apheresis Plasma Held for 18 Hours at Ambient Temperature Prior to Pathogen Inactivation (INTERCEPT™).

Jean-Pierre Cazenave, Hervé Isola, Marie-Louise Wiesel, Daniel Kientz, Michel Laforêt, Marc Slaedts, Linda Pinkoski, Yasmin Singh, Laurence Corash
Journal: Blood
Blood (2006) 108 (11): 940.
https://doi.org/10.1182/blood.V108.11.940.940
Published: 2006